ES2538338T3 - Método para la estabilización de S-nitrosoglutatión y composición preparada por el mismo - Google Patents
Método para la estabilización de S-nitrosoglutatión y composición preparada por el mismo Download PDFInfo
- Publication number
- ES2538338T3 ES2538338T3 ES09702422.8T ES09702422T ES2538338T3 ES 2538338 T3 ES2538338 T3 ES 2538338T3 ES 09702422 T ES09702422 T ES 09702422T ES 2538338 T3 ES2538338 T3 ES 2538338T3
- Authority
- ES
- Spain
- Prior art keywords
- nitrosoglutathione
- stabilization
- composition prepared
- gsno
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010001742 S-Nitrosoglutathione Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 150000004804 polysaccharides Chemical class 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002835 absorbance Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Composición farmacéutica que comprende GSNO como ingrediente activo junto con aditivos usuales y con uno o más polímeros farmacéuticamente aceptables seleccionados del grupo de polisacáridos, PVA, PVP, PEG, ácido algínico y sus sales, donde el valor de pH de la composición es aproximadamente 8-9.
Description
E09702422
02-06-2015
La Figura 4 muestra los resultados obtenidos. Es evidente que después de 36 días la descomposición de GSNO es significativamente menor en las soluciones poliméricas alcalinas.
La comparación de las figuras 3 y 4 también muestra que la mejora de la estabilidad de GSNO encontrada en condiciones alcalinas se puede aumentar más utilizando polímeros con efecto estabilizante. Los polímeros por sí
5 mismos mejoran la estabilidad de GSNO puesto que incluso el día 36 se observa un valor de absorbancia relativa de alrededor de 30 con las soluciones ácidas que contienen el polímero. Sorprendentemente, el efecto estabilizante de los polímeros se puede mejorar significativamente cuando se utilizan los polímeros en condiciones alcalinas -con las soluciones 6 y 8 los valores de absorbancia relativas son superiores a 60, esto es, se encuentra en efecto un aumento de aproximadamente el 80 %
10
8
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0800031 | 2008-01-16 | ||
| HU0800031A HU0800031D0 (en) | 2008-01-16 | 2008-01-16 | Method for stabilization of s-nitrosoglutathione and composition prepared by the same |
| PCT/HU2009/000004 WO2009090439A2 (en) | 2008-01-16 | 2009-01-16 | Method for stabilization of s-nitrosoglutathione and composition prepared by the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2538338T3 true ES2538338T3 (es) | 2015-06-19 |
Family
ID=89988005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09702422.8T Active ES2538338T3 (es) | 2008-01-16 | 2009-01-16 | Método para la estabilización de S-nitrosoglutatión y composición preparada por el mismo |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8404266B2 (es) |
| EP (1) | EP2252260B1 (es) |
| JP (1) | JP5508286B2 (es) |
| KR (1) | KR101601989B1 (es) |
| CN (2) | CN101969922B (es) |
| BR (1) | BRPI0906874A2 (es) |
| CA (1) | CA2712299C (es) |
| CY (1) | CY1116359T1 (es) |
| DK (1) | DK2252260T3 (es) |
| ES (1) | ES2538338T3 (es) |
| HK (1) | HK1153944A1 (es) |
| HR (1) | HRP20150578T1 (es) |
| HU (2) | HU0800031D0 (es) |
| PL (1) | PL2252260T3 (es) |
| PT (1) | PT2252260E (es) |
| WO (1) | WO2009090439A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2197417T3 (da) * | 2007-10-17 | 2012-06-25 | Pharmagenix Ag | Farmaceutisk sammensætning, omfattende s-nitrosoglutathion og polysaccharid |
| CN101897948B (zh) * | 2010-07-16 | 2013-03-13 | 浙江大学 | 一种s-亚硝基谷胱甘肽的用途 |
| KR101555523B1 (ko) * | 2014-02-28 | 2015-09-25 | 부산대학교 산학협력단 | 산화질소 방출성 상처치료 필름 및 이의 제조방법 |
| CN106689132A (zh) * | 2016-12-30 | 2017-05-24 | 中国农业科学院麻类研究所 | 一种提高红麻幼苗期耐镉性能的组合物 |
| CN107823627A (zh) * | 2017-12-01 | 2018-03-23 | 成都卓阳生物科技有限公司 | 一种还原型谷胱甘肽在制备治疗糖尿病足涂沫药剂中的应用 |
| WO2019236825A1 (en) * | 2018-06-08 | 2019-12-12 | University Of Georgia Research Foundation, Inc. | Antimicrobial compositions with wound healing properties |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9504350D0 (en) * | 1995-03-04 | 1995-04-26 | Sod Conseils Rech Applic | Arginine derivatives |
| US20070185205A1 (en) * | 2000-01-14 | 2007-08-09 | Hunt John F | Airway Alkalinization as Therapy for Airway Diseases |
| WO2001070199A1 (en) | 2000-03-20 | 2001-09-27 | Novovascular, Inc. | Matrices containing nitric oxide donors and reducing agents and their use |
| US20020002136A1 (en) * | 2000-06-28 | 2002-01-03 | Hebert Rolland F. | Salts of glutathione |
| CN1531546A (zh) * | 2001-01-02 | 2004-09-22 | ����ҩƷ��ҵ��ʽ���� | 肽化合物 |
| ATE485849T1 (de) * | 2005-12-02 | 2010-11-15 | Univ Michigan | Polymerzusammensetzungen, überzüge und vorrichtungen und herstellungs- und anwendungsverfahren damit |
| DK2197417T3 (da) * | 2007-10-17 | 2012-06-25 | Pharmagenix Ag | Farmaceutisk sammensætning, omfattende s-nitrosoglutathion og polysaccharid |
-
2008
- 2008-01-16 HU HU0800031A patent/HU0800031D0/hu unknown
-
2009
- 2009-01-16 PL PL09702422T patent/PL2252260T3/pl unknown
- 2009-01-16 EP EP09702422.8A patent/EP2252260B1/en active Active
- 2009-01-16 JP JP2010542695A patent/JP5508286B2/ja not_active Expired - Fee Related
- 2009-01-16 KR KR1020107017003A patent/KR101601989B1/ko active IP Right Grant
- 2009-01-16 WO PCT/HU2009/000004 patent/WO2009090439A2/en active Application Filing
- 2009-01-16 BR BRPI0906874-0A patent/BRPI0906874A2/pt not_active Application Discontinuation
- 2009-01-16 ES ES09702422.8T patent/ES2538338T3/es active Active
- 2009-01-16 CA CA2712299A patent/CA2712299C/en active Active
- 2009-01-16 PT PT97024228T patent/PT2252260E/pt unknown
- 2009-01-16 CN CN2009801077972A patent/CN101969922B/zh not_active Expired - Fee Related
- 2009-01-16 DK DK09702422.8T patent/DK2252260T3/en active
- 2009-01-16 US US12/863,816 patent/US8404266B2/en active Active
- 2009-01-16 CN CN2013102937033A patent/CN103417973A/zh active Pending
- 2009-01-16 HU HUE09702422A patent/HUE025573T2/en unknown
-
2011
- 2011-08-09 HK HK11108321.0A patent/HK1153944A1/xx not_active IP Right Cessation
-
2015
- 2015-05-29 HR HRP20150578TT patent/HRP20150578T1/hr unknown
- 2015-06-03 CY CY20151100493T patent/CY1116359T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009090439A2 (en) | 2009-07-23 |
| EP2252260A2 (en) | 2010-11-24 |
| EP2252260B1 (en) | 2015-03-04 |
| HK1153944A1 (en) | 2012-04-20 |
| PT2252260E (pt) | 2015-07-09 |
| DK2252260T3 (en) | 2015-06-08 |
| CY1116359T1 (el) | 2017-02-08 |
| JP5508286B2 (ja) | 2014-05-28 |
| US20110136910A1 (en) | 2011-06-09 |
| HU0800031D0 (en) | 2008-03-28 |
| HUE025573T2 (en) | 2016-04-28 |
| HRP20150578T1 (hr) | 2015-08-14 |
| KR101601989B1 (ko) | 2016-03-09 |
| CA2712299C (en) | 2016-10-11 |
| US8404266B2 (en) | 2013-03-26 |
| CN101969922A (zh) | 2011-02-09 |
| JP2011509993A (ja) | 2011-03-31 |
| CN101969922B (zh) | 2013-07-10 |
| CA2712299A1 (en) | 2009-07-23 |
| BRPI0906874A2 (pt) | 2019-02-19 |
| KR20100127206A (ko) | 2010-12-03 |
| PL2252260T3 (pl) | 2015-08-31 |
| CN103417973A (zh) | 2013-12-04 |
| WO2009090439A3 (en) | 2009-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2538338T3 (es) | Método para la estabilización de S-nitrosoglutatión y composición preparada por el mismo | |
| CL2017001139A1 (es) | Composiciones de antibiótico | |
| UY38196A (es) | Inhibidores de cinasa dependientes de ciclina | |
| ES2663817T3 (es) | Proceso para producir una disolución inyectable estable de noradrenalina a baja concentración | |
| ECSP17073965A (es) | Derivados de ciclohexano sustituido con amido | |
| DOP2013000172A (es) | Composicion farmaceutica | |
| CO6311052A2 (es) | Una microemulsion que comprende un ingrediente activo, un solvente y un surfactante no ionico y proceso para su preparación | |
| CO2019001448A2 (es) | Composiciones y métodos para estabilizar flavivirus con formulaciones mejoradas | |
| AR079890A1 (es) | Estabilizacion de peliculas de oxido de zinc en composiciones bucales | |
| BR112015015170A8 (pt) | sal de sódio cristalino do ácido 2-o-alfa-d-glicosil-l-ascórbico, composição e método de produção do referido sal | |
| PE20151793A1 (es) | Compuestos heterociclicos moduladores de la piruvato quinasa y composiciones que los contienen | |
| ECSP11010833A (es) | Procedimiento para controlar la degradación de un ingrediente activo químico agrícola | |
| ES2560676T3 (es) | Combinación farmacéutica para el tratamiento del dolor | |
| BR112016022394A2 (pt) | Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável | |
| CR20160433A (es) | Nuevos compuestos | |
| ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
| AR086956A1 (es) | Formulaciones liofilizadas de fgf-18 | |
| CR20160462A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
| NI201900063A (es) | Amidas aromáticas de ácido carboxílico | |
| AR100618A1 (es) | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| ES2895690T1 (es) | Método para producir una solución de éster de bortezomib | |
| EA201691825A1 (ru) | Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта) | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
| CO2023004926A2 (es) | Compuestos de triazolopiridinilo como inhibidores de quinasas |